Calypte Raises $5.2 Million in Private Placement
Following this financing, Marr owns over 19% of our outstanding common stock. Mr. Khidasheli and his co-investors have built an extensive network of important contacts in many of our target markets, including India, Russia, Thailand, French-speaking Africa, the Middle East and China. We believe these contacts and resources will complement our own. We expect to leverage these relationships with the financial support provided by this arrangement. In addition to this initial $5 million investment, the financing also includes an intermediate package of warrants that can be a source of up to $13.5 million in additional funding over the next 18 months.
"We believe we are poised to take advantage of market opportunities, fulfilling important humanitarian needs starting with our non-invasive diagnostic test that serves as a first step in the fight against HIV/AIDS." Roger Gale - CEO
*************************************************************************************************************************************************************
CYPT just got their financial house in order for international launch of their product sweet. They have been lining up countries for HIV-1/2 Rapid Test sales and have made great inroads into manufacturing and production ISO plants in both China as well as Thailand...
All the Best, JP
AI
